TY - JOUR
T1 - Ibrutinib for the treatment of Waldenström macroglobulinemia
AU - Chakraborty, Rajshekhar
AU - Kapoor, Prashant
AU - Ansell, Stephen M.
AU - Gertz, Morie A.
N1 - Publisher Copyright:
© 2015 © Informa UK, Ltd.
PY - 2015/9/3
Y1 - 2015/9/3
N2 - Waldenström macroglobulinemia (WM) is a B-cell non-Hodgkin lymphoma (NHL) characterized by IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Until recently, there was no drug specifically approved for WM by the US FDA, leading to wide variations in therapeutic strategies across the globe. Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is the first drug approved specifically for WM by the FDA after a clinical trial showed impressive response in previously treated WM. Ibrutinib is a non-stem cell toxic and non-neurotoxic option and suitable for long-Term oral maintenance therapy, with the potential of improving survival in WM. With identification of novel genetic mutations impacting response to ibrutinib, it would be possible to individualize therapy based on MYD88 and CXCR4 genotypes. However, long-Term safety and efficacy data are required, and cost-effectiveness needs to be addressed before ibrutinib can gain widespread acceptance for front-line therapy of WM.
AB - Waldenström macroglobulinemia (WM) is a B-cell non-Hodgkin lymphoma (NHL) characterized by IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Until recently, there was no drug specifically approved for WM by the US FDA, leading to wide variations in therapeutic strategies across the globe. Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is the first drug approved specifically for WM by the FDA after a clinical trial showed impressive response in previously treated WM. Ibrutinib is a non-stem cell toxic and non-neurotoxic option and suitable for long-Term oral maintenance therapy, with the potential of improving survival in WM. With identification of novel genetic mutations impacting response to ibrutinib, it would be possible to individualize therapy based on MYD88 and CXCR4 genotypes. However, long-Term safety and efficacy data are required, and cost-effectiveness needs to be addressed before ibrutinib can gain widespread acceptance for front-line therapy of WM.
KW - Waldenström macroglobulinemia
KW - bruton tyrosine kinase
KW - ibrutinib
KW - immunoglobin M
KW - lymphoplasmacytic lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84941216456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941216456&partnerID=8YFLogxK
U2 - 10.1586/17474086.2015.1061427
DO - 10.1586/17474086.2015.1061427
M3 - Article
C2 - 26138997
AN - SCOPUS:84941216456
SN - 1747-4086
VL - 8
SP - 569
EP - 579
JO - Expert Review of Hematology
JF - Expert Review of Hematology
IS - 5
ER -